 SYDNEY , June 30, 2021 PRNewswire -- Kazia Therapeutics Limited NASDAQ: KZIA; ASX: KZA, an oncology-focused drug development company, is pleased to provide an update on recent progress with its two pipeline assets, paxalisib and EVT801. Key Points GBM AGILE pivotal study of paxalisib is recruiting ahead of expectations, with almost 25 sites now open to the paxalisib arm. 